Get the Stockscreener App
78.83
2.10%
1.62
Henry Schein Inc stock is traded at $78.83, with a volume of 1.00M.
It is up +2.10% in the last 24 hours and up +5.29% over the past month.
Henry Schein Inc is a solutions company for healthcare professionals. It offers healthcare equipment, products, and services to office-based dental and medical practitioners, as well as alternative sites of care. The company's reportable segments are: Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology. It generates maximum revenue from the Global Distribution and Value-Added Services segment, which includes distribution to the dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services. This segment also includes value-added services such as financial services, continuing education services, consulting, and other practice services.
See More
Previous Close:
$77.21
Open:
$78.04
24h Volume:
1.00M
Relative Volume:
0.77
Market Cap:
$9.05B
Revenue:
$13.18B
Net Income/Loss:
$419.00M
P/E Ratio:
24.10
EPS:
3.2704
Net Cash Flow:
$521.00M
1W Performance:
+4.63%
1M Performance:
+5.29%
6M Performance:
+25.17%
1Y Performance:
+21.78%
1-Day Range:
$78.03
$79.96
1-Week Range:
$74.18
$79.96
52-Week Range:
$61.95
$89.29
Henry Schein Inc Stock (HSIC) Company Profile
Name
Henry Schein Inc
Sector
Industry
Phone
(631) 843-5500
Address
135 DURYEA RD, MELVILLE, NY
Compare HSIC vs MCK, COR, CAH, AHG
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HSIC
Henry Schein Inc
|
78.83 | 8.86B | 13.18B | 419.00M | 521.00M | 3.2704 |
MCK
Mckesson Corporation
|
866.38 | 106.24B | 397.96B | 4.55B | 9.64B | 34.77 |
COR
Cencora Inc
|
327.56 | 62.71B | 325.78B | 1.64B | 3.61B | 8.3139 |
CAH
Cardinal Health Inc
|
213.99 | 50.15B | 244.67B | 1.68B | 5.51B | 6.9487 |
AHG
Akso Health Group Adr
|
2.00 | 1.82B | 14.85M | -136.07M | 7.25M | -0.4726 |
Henry Schein Inc Stock (HSIC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-16-26 | Initiated | BTIG Research | Neutral |
| Apr-15-26 | Initiated | Citigroup | Buy |
| Feb-23-26 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Aug-26-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-25-25 | Downgrade | Stifel | Buy → Hold |
| Jul-14-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-14-25 | Initiated | Wells Fargo | Equal Weight |
| Jan-06-25 | Upgrade | BofA Securities | Underperform → Buy |
| Dec-04-24 | Initiated | Mizuho | Neutral |
| Jul-22-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Dec-12-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-10-23 | Upgrade | Stifel | Hold → Buy |
| Aug-08-22 | Upgrade | UBS | Sell → Neutral |
| Jul-21-22 | Downgrade | Goldman | Buy → Neutral |
| Jun-14-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-13-22 | Resumed | Credit Suisse | Outperform |
| Jan-31-22 | Initiated | Morgan Stanley | Underweight |
| Jan-07-22 | Upgrade | Credit Suisse | Neutral → Outperform |
| Oct-01-21 | Resumed | Credit Suisse | Neutral |
| Feb-08-21 | Resumed | Piper Sandler | Overweight |
| Jan-04-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Nov-03-20 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| May-06-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Apr-07-20 | Upgrade | Goldman | Neutral → Buy |
| Apr-02-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-09-20 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jan-02-20 | Upgrade | Evercore ISI | Underperform → In-line |
| Aug-07-19 | Downgrade | William Blair | Outperform → Mkt Perform |
| May-30-19 | Initiated | Wolfe Research | Underperform |
| May-15-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-18-19 | Initiated | Guggenheim | Buy |
| Jan-17-19 | Initiated | UBS | Sell |
| Jan-03-19 | Downgrade | Evercore ISI | In-line → Underperform |
| Jan-02-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-08-18 | Reiterated | Barrington Research | Outperform |
| Oct-25-18 | Downgrade | Edward Jones | Hold → Sell |
| Oct-19-18 | Resumed | Goldman | Neutral |
| Oct-04-18 | Reiterated | Robert W. Baird | Outperform |
| Aug-07-18 | Reiterated | Stifel | Hold |
| Apr-24-18 | Downgrade | Goldman | Buy → Neutral |
| Apr-04-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
View All
Henry Schein Inc Stock (HSIC) Latest News
Henry Schein (NASDAQ:HSIC) Rating Increased to Strong-Buy at Wall Street Zen - MarketBeat
Henry Schein Inc. stock outperforms competitors on strong trading day - MarketWatch
Why Henry Schein (HSIC) is Poised to Beat Earnings Estimates Again - Yahoo Finance
BTIG initiates Henry Schein stock coverage with Neutral on modest growth - Investing.com Canada
Citigroup initiates coverage of Henry Schein (HSIC) with buy recommendation - MSN
Citigroup Initiates Henry Schein at Buy With $100 Price Target - Moomoo
Henry Schein (HSIC) down 9.4% since last earnings report: Can it rebound? - MSN
Henry Schein (HSIC) Valuation Check As Board Restructuring And Leadership Changes Take Shape - Sahm
Why Henry Schein (HSIC) is a Top Growth Stock for the Long-Term - Yahoo Finance
Henry Schein shrinks board as long-serving chairman retires - MSN
Henry Schein (HSIC) price target increased by 12.37% to 90.80 - MSN
Henry Schein’s Board Overhaul and Bergman Exit Might Change The Case For Investing In HSIC - simplywall.st
What to expect from Henry Schein’s Q1 2026 earnings report - MSN
At US$75.34, Is Henry Schein, Inc. (NASDAQ:HSIC) Worth Looking At Closely? - Moomoo
What to Expect From Henry Schein’s Q1 2026 Earnings Report - Barchart.com
How Investors Are Reacting To Henry Schein (HSIC) Board Overhaul After Bergman’s Retirement - Yahoo Finance
Palestra Capital Management LLC's Henry Schein Inc(HSIC) Holding History - GuruFocus
A Look At Henry Schein (HSIC) Valuation As Board Overhaul Reshapes Governance - Yahoo Finance
Henry Schein Inc. stock rises Wednesday, still underperforms market - MarketWatch
HSIC Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Henry Schein board to shrink to 10 members after annual meeting By Investing.com - Investing.com South Africa
Henry Schein Announces Board Reduction Plan - dentistrytoday.com
Henry Schein, Inc. Announces Board Retirements - marketscreener.com
Henry Schein (HSIC) Announces Board of Directors Restructuring - GuruFocus
Henry Schein : 2026 Proxy Statement of 2025 - marketscreener.com
Henry Schein board to shrink to 10 members after annual meeting - Investing.com
Henry Schein (HSIC) 2026 proxy details CEO transition, KKR 16.4% stake and board cuts - Stock Titan
Henry Schein to Reduce Size of the Board of Directors following 2026 Annual Meeting of Stockholders - Business Wire
Williams, Henry Schein, and 3 Other Bargain Stocks From a Veteran Value Fund Manager - Barron's
Henry Schein, Inc. (NASDAQ:HSIC) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
231,651 Shares in Henry Schein, Inc. $HSIC Acquired by Tudor Investment Corp ET AL - MarketBeat
HSIC Technical Analysis & Stock Price Forecast - Intellectia AI
Assessing Henry Schein (HSIC) Valuation As Recent Share Price Moves Draw Fresh Attention - Sahm
Henry Schein, Inc. (HSIC) stock price, news, quote and history - Yahoo Finance UK
Entry Recap: Is Henry Schein Inc still a buy after recent gainsTrade Ideas & Low Risk Entry Point Tips - baoquankhu1.vn
Henry Schein, Inc. (HSIC) Stock Forecasts - Yahoo Finance
List of 35 Acquisitions by Henry Schein (Apr 2026) - Tracxn
Henry Schein Inc. stock rises Tuesday, still underperforms market - MarketWatch
Henry Schein Inc Stock: A Steady Force in Dental and Medical Distribution for North American Investo - AD HOC NEWS
Why Henry Schein (HSIC) is a Top Value Stock for the Long-Term - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Henry Schein (HSIC), Encompass Health (EHC) and Merck & Company (MRK) - The Globe and Mail
Henry Schein: A Cash-Generating Healthcare Distributor Priced fo - GuruFocus
Henry Schein: A Cash-Generating Healthcare Distributor Priced for Mediocrity - TradingView
Henry Schein, Inc. (NASDAQ:HSIC) Short Interest Update - MarketBeat
Assenagon Asset Management S.A. Buys 45,701 Shares of Henry Schein, Inc. $HSIC - MarketBeat
Henry Schein Inc Stock (HSIC) Financials Data
Revenue
Net Income
Cash Flow
EPS
6.10%
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):